Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imfinzi Sequential Therapy in Advanced NSCLC
NCT02179671Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02179671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179671.